{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:00:58Z","timestamp":1785470458812,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00277-023-05213-6","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T10:02:16Z","timestamp":1683280936000},"page":"1731-1738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease"],"prefix":"10.1007","volume":"102","author":[{"given":"Yao-jia","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-nong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-0436","authenticated-orcid":false,"given":"Hong-hu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"5213_CR1","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41375-019-0697-0","volume":"34","author":"S Opatz","year":"2020","unstructured":"Opatz S, Bamopoulos SA, Metzeler KH et al (2020) The clinical mutatome of core binding factor leukemia. Leukemia 34:1553\u20131562","journal-title":"Leukemia"},{"key":"5213_CR2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc840","volume":"2","author":"NA Speck","year":"2002","unstructured":"Speck NA, Gilliland DG (2002) Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2:502\u2013513","journal-title":"Nat Rev Cancer"},{"key":"5213_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447","journal-title":"Blood"},{"key":"5213_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41408-021-00503-6","volume":"11","author":"G Borthakur","year":"2021","unstructured":"Borthakur G, Kantarjian H (2021) Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J 11:114","journal-title":"Blood Cancer J"},{"key":"5213_CR5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","volume":"341","author":"B L\u00f6wenberg","year":"1999","unstructured":"L\u00f6wenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341:1051\u20131062","journal-title":"N Engl J Med"},{"key":"5213_CR6","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1182\/blood.V77.7.1429.1429","volume":"77","author":"GL Phillips","year":"1991","unstructured":"Phillips GL, Reece DE, Shepherd JD et al (1991) High dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 77:1429\u20131435","journal-title":"Blood"},{"key":"5213_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2141.2006.06276.x","volume":"135","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum FR, Kopecky KJ, Tallman MS et al (2006) The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 135:165\u2013173","journal-title":"Br J Haematol"},{"key":"5213_CR8","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1200\/JCO.2004.03.012","volume":"22","author":"RF Schlenk","year":"2004","unstructured":"Schlenk RF, Benner A, Krauter J et al (2004) Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22:3741\u20133750","journal-title":"J Clin Oncol"},{"key":"5213_CR9","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1200\/JCO.2005.15.610","volume":"23","author":"G Marcucci","year":"2005","unstructured":"Marcucci G, Mr\u00f3zek K, Ruppert AS et al (2005) Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a cancer and leukemia group B study. J Clin Oncol 23:5705\u20135717","journal-title":"J Clin Oncol"},{"key":"5213_CR10","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","volume":"120","author":"MR Loken","year":"2012","unstructured":"Loken MR, Alonzo TA, Pardo L et al (2012) Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children\u2019s Oncology Group. Blood 120:1581\u20131588","journal-title":"Blood"},{"key":"5213_CR11","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","volume":"31","author":"SD Freeman","year":"2013","unstructured":"Freeman SD, Virgo P, Couzens S et al (2013) Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol: Off J Ame Soc Clin Oncol 31:4123\u20134131","journal-title":"J Clin Oncol: Off J Ame Soc Clin Oncol"},{"key":"5213_CR12","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2014-05-577593","volume":"124","author":"D Grimwade","year":"2014","unstructured":"Grimwade D, Freeman SD (2014) Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for \u201cprime time\u201d? Blood 124:3345\u20133355","journal-title":"Blood"},{"key":"5213_CR13","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1038\/s41375-018-0158-1","volume":"32","author":"P Boddu","year":"2018","unstructured":"Boddu P, Gurguis C, Sanford D et al (2018) Response kinetics and factors predicting survival in core-binding factor leukemia. Leukemia 32:2698\u20132701","journal-title":"Leukemia"},{"key":"5213_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ajcp\/aqw038","volume":"145","author":"J Ouyang","year":"2016","unstructured":"Ouyang J, Goswami M, Peng J et al (2016) Comparison of multiparameter flow cytometry immunophenotypic analysis and quantitative RT-PCR for the detection of minimal residual disease of core binding factor acute myeloid leukemia. Am J Clin Pathol 145:769\u2013777","journal-title":"Am J Clin Pathol"},{"key":"5213_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-8722-4-46","volume":"4","author":"G Wei","year":"2011","unstructured":"Wei G, Ni W, Chiao J-w et al (2011) A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol 4:46","journal-title":"J Hematol Oncol"},{"key":"5213_CR16","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3109\/10428194.2013.776679","volume":"54","author":"HH Zhu","year":"2013","unstructured":"Zhu HH, Jiang H, Jiang B et al (2013) Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy. Leuk Lymphoma 54:2452\u20132457","journal-title":"Leuk Lymphoma"},{"key":"5213_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","volume":"19","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Bixby D, Perl A et al (2021) NCCN guidelines insights: acute myeloid leukemia, Version 2.2021. J Natl Compr Canc Netw 19:16\u201327","journal-title":"J Natl Compr Canc Netw"},{"key":"5213_CR18","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood.2019002959","volume":"135","author":"R Dillon","year":"2020","unstructured":"Dillon R, Hills R, Freeman S et al (2020) Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood 135:680\u2013688","journal-title":"Blood"},{"key":"5213_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629","journal-title":"N Engl J Med"},{"key":"5213_CR20","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C et al (2020) Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol 6:1890\u20131899","journal-title":"JAMA Oncol"},{"key":"5213_CR21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377","journal-title":"Blood"},{"key":"5213_CR22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.canlet.2016.12.019","volume":"400","author":"ME Cazzaniga","year":"2017","unstructured":"Cazzaniga ME, Dionisio MR, Riva F (2017) Metronomic chemotherapy for advanced breast cancer patients. Cancer Lett 400:252\u2013258","journal-title":"Cancer Lett"},{"key":"5213_CR23","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1182\/blood-2005-04-1422","volume":"106","author":"Y Shaked","year":"2005","unstructured":"Shaked Y, Emmenegger U, Man S et al (2005) Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106:3058\u20133061","journal-title":"Blood"},{"key":"5213_CR24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.canlet.2016.11.007","volume":"400","author":"AS Abu Lila","year":"2017","unstructured":"Abu Lila AS, Ishida T (2017) Metronomic chemotherapy and nanocarrier platforms. Cancer Lett 400:232\u2013242","journal-title":"Cancer Lett"},{"key":"5213_CR25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa025406","volume":"349","author":"B L\u00f6wenberg","year":"2003","unstructured":"L\u00f6wenberg B, van Putten W, Theobald M et al (2003) Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute Myeloid Leukemia. N Engl J Med 349:743\u2013752","journal-title":"N Engl J Med"},{"key":"5213_CR26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0145-2126(93)90089-4","volume":"17","author":"M Tanaka","year":"1993","unstructured":"Tanaka M (1993) Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow. Leuk Res 17:585\u2013592","journal-title":"Leuk Res"},{"key":"5213_CR27","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1182\/blood.V73.5.1272.bloodjournal7351272","volume":"73","author":"JKC Miyauchi","year":"1989","unstructured":"Miyauchi JKC, Wang C et al (1989) Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 73:1272\u20131278","journal-title":"Blood"},{"key":"5213_CR28","first-page":"1480","volume":"8","author":"PA Te Boekhorst","year":"1994","unstructured":"Te Boekhorst PA, L B, Sonneveld P (1994) Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia 8:1480\u20131486","journal-title":"Leukemia"},{"key":"5213_CR29","first-page":"1191","volume":"7","author":"PA Te Boekhorst","year":"1993","unstructured":"Te Boekhorst PA, L B, Vlastuin M, Sonneveld P (1993) Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia 7:1191\u20131198","journal-title":"Leukemia"},{"key":"5213_CR30","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","volume":"364","author":"B L\u00f6wenberg","year":"2011","unstructured":"L\u00f6wenberg B, Pabst T, Vellenga E et al (2011) Cytarabine dose for acute myeloid leukemia. N Engl J Med 364:1027\u20131036","journal-title":"N Engl J Med"},{"key":"5213_CR31","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2010-07-295279","volume":"117","author":"S Miyawaki","year":"2011","unstructured":"Miyawaki S, Ohtake S, Fujisawa S et al (2011) A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 study. Blood 117:2366\u20132372","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05213-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05213-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05213-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T06:04:23Z","timestamp":1686549863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05213-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["5213"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05213-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"assertion":[{"value":"30 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institute Research Ethics Committee of the first Affiliated Hospital, College of Medicine, Zhejiang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}